Case Study 11: Considerations for Enzyme Mapping Experiments-Interaction Between the Aldehyde Oxidase Inhibitor Hydralazine and Glutathione.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2021
Historique:
entrez: 17 7 2021
pubmed: 18 7 2021
medline: 24 8 2021
Statut: ppublish

Résumé

Often it may be convenient and efficient to address multiple research questions with a single experiment. In many instances, however, the best approach is to design the experiment to address one question at a time. The design of enzyme mapping experiments is discussed in this chapter, focusing on considerations pertinent to the study of aldehyde oxidase (AO) vs. cytochrome P450 metabolism. Specifically, a case is presented in which reduced glutathione (GSH) was included in an experiment with human liver S9 fraction to trap reactive metabolites generated from cytochrome P450-mediated metabolism of lapatinib and its O-dealkylated metabolite, M1 (question 1). The AO inhibitor hydralazine was included in this experiment to investigate the involvement of AO-mediated metabolism of M1 (question 2). The presence of GSH was found to interfere with the inhibitory activity of hydralazine. Consideration of the time-dependent nature of hydralazine inhibitory activity toward AO when designing this experiment could have predicted the potential for GSH to interfere with hydralazine. This case underscores the importance of clearly identifying the research question, tailoring the experimental protocol to answer that question, and then meticulously considering how the experimental conditions could influence the results, particularly if attempting to address multiple questions with a single experiment.

Identifiants

pubmed: 34272718
doi: 10.1007/978-1-0716-1554-6_30
pmc: PMC9147050
mid: NIHMS1807316
doi:

Substances chimiques

Lapatinib 0VUA21238F
Hydralazine 26NAK24LS8
Cytochrome P-450 Enzyme System 9035-51-2
Aldehyde Oxidase EC 1.2.3.1
Glutathione GAN16C9B8O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

809-823

Subventions

Organisme : NCI NIH HHS
ID : K01 CA190711
Pays : United States

Informations de copyright

© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Références

Drug Metab Dispos. 2013 Jan;41(1):24-9
pubmed: 22996261
Drug Metab Dispos. 2012 Jan;40(1):139-50
pubmed: 21965624
Annu Rev Pharmacol Toxicol. 2005;45:177-202
pubmed: 15822174
J Med Chem. 2010 Dec 23;53(24):8441-60
pubmed: 20853847
Chem Res Toxicol. 2004 Jan;17(1):3-16
pubmed: 14727914
Mol Pharmacol. 2010 Oct;78(4):693-703
pubmed: 20624855
Drug Metab Lett. 2016;10(2):83-90
pubmed: 26902079
Curr Drug Metab. 2005 Jun;6(3):161-225
pubmed: 15975040
Drug Metab Dispos. 2012 Jul;40(7):1441-8
pubmed: 22522748
Exp Toxicol Pathol. 1996 Jul;48(5):439-46
pubmed: 8765689
Pharmacol Ther. 2019 Sep;201:137-180
pubmed: 31128989
J Pharm Sci. 2019 Apr;108(4):1627-1630
pubmed: 30448524
Biochem Pharmacol. 1987 Aug 15;36(16):2667-72
pubmed: 3038130
Drug Metab Dispos. 2015 Jan;43(1):163-81
pubmed: 25297949
Handb Exp Pharmacol. 2010;(196):511-44
pubmed: 20020275
Biochem Pharmacol. 1985 Dec 15;34(24):4251-6
pubmed: 3841000
Chem Res Toxicol. 2014 Apr 21;27(4):674-82
pubmed: 24502259
Arch Toxicol. 2016 Apr;90(4):753-80
pubmed: 26920149
Chem Res Toxicol. 2009 Feb;22(2):332-40
pubmed: 19161298
Drug Metab Dispos. 2004 Jan;32(1):89-97
pubmed: 14709625
Drug Metab Dispos. 2018 Jun;46(6):846-859
pubmed: 29615437
Drug Metab Dispos. 2019 Nov;47(11):1257-1269
pubmed: 31492693
Drug Metab Dispos. 2019 Jan;47(1):26-37
pubmed: 30337443
Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):153-68
pubmed: 23231678
Drug Metab Dispos. 1983 May-Jun;11(3):179-83
pubmed: 6135572
Pharm Res. 2012 Jul;29(7):1960-76
pubmed: 22415140

Auteurs

Rachel D Crouch (RD)

Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, Nashville, TN, USA.

Jessica L Beers (JL)

Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, NC, USA.

Klarissa D Jackson (KD)

Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, NC, USA. klarissa.jackson@unc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH